Stock Traders Purchase Large Volume of TG Therapeutics Call Options (NASDAQ:TGTX)

TG Therapeutics, Inc. (NASDAQ:TGTX) saw some unusual options trading activity on Wednesday. Stock investors acquired 7,870 call options on the stock. This is an increase of 119% compared to the typical daily volume of 3,597 call options.

Insider Activity

In other news, Director Yann Echelard sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the sale, the director owned 223,816 shares in the company, valued at approximately $7,289,687.12. This trade represents a 2.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 10.64% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in TGTX. Ameritas Advisory Services LLC bought a new stake in TG Therapeutics in the second quarter valued at approximately $25,000. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics in the 2nd quarter worth approximately $25,000. Danske Bank A S acquired a new stake in shares of TG Therapeutics during the third quarter worth $25,000. Optiver Holding B.V. increased its position in shares of TG Therapeutics by 3,485.7% during the third quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 732 shares during the period. Finally, Bessemer Group Inc. raised its stake in TG Therapeutics by 117.1% during the third quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 486 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Trading Up 6.0%

Shares of TGTX stock opened at $29.54 on Thursday. TG Therapeutics has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The stock’s fifty day moving average price is $30.85 and its two-hundred day moving average price is $32.58. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The company has a market cap of $4.69 billion, a PE ratio of 10.63 and a beta of 1.86.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share for the quarter, topping the consensus estimate of $0.24 by $2.19. The business had revenue of $161.71 million during the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.TG Therapeutics’s revenue for the quarter was up 92.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.02 EPS. Equities analysts predict that TG Therapeutics will post 0.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on TGTX shares. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday. HC Wainwright assumed coverage on TG Therapeutics in a research report on Monday, October 6th. They set a “buy” rating and a $60.00 price target on the stock. B. Riley upgraded TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, December 14th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $50.75.

Key TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 net product revenue beat internal guidance and the company gave a positive 2026 revenue outlook, helping push shares higher; analysts and investors highlighted upcoming Briumvi pipeline milestones as additional upside. TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results
• Positive Sentiment: Company press release / investor communications reiterated preliminary Q4/2025 figures and 2026 guidance and listed anticipated development milestones — this official disclosure underpins the market’s positive reaction. TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
• Positive Sentiment: Retail-trader interest and flow/momentum amplified gains: media coverage notes retail buying, and options activity showed a large surge in call purchases (≈7,870 calls, ~119% above normal), consistent with short‑term bullish positioning. Retail traders are piling into TG Therapeutics – what’s driving the chatter?
• Neutral Sentiment: TGTX presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for pipeline/management color but no single market‑moving revelation in the transcript itself. TGTX Presents at 44th Annual J.P. Morgan Healthcare Conference — Transcript
• Neutral Sentiment: Database entries show the company “updated” FY2025 and FY2026 EPS guidance but the published entries here lack specific EPS numbers — until full guidance details are confirmed, impact is unclear.
• Negative Sentiment: HC Wainwright trimmed several forward EPS estimates (Q4‑2026 cut to $0.47 from $0.51; modest cuts to FY2026, FY2028, FY2029 forecasts) — the revisions are small but introduce some downward pressure on longer‑term expectations. HC Wainwright nevertheless retains a Buy rating and $60 price target, which tempers the downgrade impact.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.